We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Fresenius Medical (FMS) Q1 Earnings Miss Estimates, Fall Y/Y
Read MoreHide Full Article
Fresenius Medical Care AG & Co. KGaA (FMS - Free Report) reported adjusted earnings per share (EPS) of 52 cents in first-quarter 2020, which missed the Zacks Consensus Estimate of 62 cents by 16.1%. Moreover, the bottom line declined 11.9% year over year.
Revenues improved 5.5% year over year to $4.95 billion and beat the Zacks Consensus Estimate by 1.2%.
Segmental Details
In the first quarter, Fresenius Medical reported through two segments — Health Care Services and Health Care Products.
Health Care Services revenues improved 8% on a year-over-year basis and 7% at constant currency (cc). The improvement came on the back of growth in same market treatments, contributions from acquisitions, and increase in dialysis days.
Health Care Products revenues climbed 10% year over year and 9% at cc. The upside can primarily be attributed to higher sales of products for acute care treatments, renal pharmaceuticals and bloodlines. Lower volume of sales of dialysis machines partially negated the upside.
Fresenius Medical Care AG Co KGaA Price, Consensus and EPS Surprise
Revenues in the region grew 10% year over year and 7% at cc. On organic basis, sales in the region improved 3%.
EMEA
Revenues in this region increased 4% year over year and 4% cc in the quarter. On organic basis, sales in the region advanced 3%.
Asia-Pacific
Revenues in this region improved 4% year over year and 3% at cc in the reported quarter. On an organic basis, sales in the region improved 2%.
Latin America
Revenues in Latin America rose 4% year over year and 24% at cc. Organic growth in region was 17%.
Guidance
Following is the outlook provided in February, which excludes the impact of the COVID-19 pandemic.
For 2020, the company expects adjusted revenues and adjusted net income to improve at a mid-to-high-single digit rate.
Summing Up
Fresenius Medical reported mixed results in the first quarter. The company continues to gain from Health Care Products and Services units, which witnessed revenue growth in the quarter under review. Revenues in the North American, EMEA and Asia-Pacific regions also improved. In fact, management remains optimistic regarding the buyouts of Sound Physicians and NxStage Medical.
Furthermore, strong view for 2020 paints a brighter picture. Revenue growth in the reported quarter highlights the company’s underlying business development remaining intact and resiliency of its business model.
However, Fresenius Medical faces intense competition in the field of health care services, and sale of dialysis products, which remains a concern.
Zacks Rank
The company carries a Zacks Rank of 4 (Sell).
Key Picks
Some better-ranked stocks in the broader medical space are Aphria Inc. , Biogen Inc. (BIIB - Free Report) and Eli Lilly and Company (LLY - Free Report) .
Aphria reported third-quarter fiscal 2020 adjusted EPS of 2 cents, beating the Zacks Consensus Estimate of a loss of 4 cents. Net revenues of $64.4 million surpassed the consensus mark by 14.6%. The company carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Biogen currently carries a Zacks Rank #2. It reported first-quarter 2020 adjusted EPS of $9.14, surpassing the Zacks Consensus Estimate by 18.1%. Revenues of $3.53 billion outpaced the consensus mark by 3.2%.
Eli Lilly reported first-quarter 2020 EPS of $1.75, outpacing the Zacks Consensus Estimate by 12.9%. Revenues of $145.3 million surpassed the consensus estimate by 6.3%. The company currently sports a Zacks Rank #1.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Fresenius Medical (FMS) Q1 Earnings Miss Estimates, Fall Y/Y
Fresenius Medical Care AG & Co. KGaA (FMS - Free Report) reported adjusted earnings per share (EPS) of 52 cents in first-quarter 2020, which missed the Zacks Consensus Estimate of 62 cents by 16.1%. Moreover, the bottom line declined 11.9% year over year.
Revenues improved 5.5% year over year to $4.95 billion and beat the Zacks Consensus Estimate by 1.2%.
Segmental Details
In the first quarter, Fresenius Medical reported through two segments — Health Care Services and Health Care Products.
Health Care Services revenues improved 8% on a year-over-year basis and 7% at constant currency (cc). The improvement came on the back of growth in same market treatments, contributions from acquisitions, and increase in dialysis days.
Health Care Products revenues climbed 10% year over year and 9% at cc. The upside can primarily be attributed to higher sales of products for acute care treatments, renal pharmaceuticals and bloodlines. Lower volume of sales of dialysis machines partially negated the upside.
Fresenius Medical Care AG Co KGaA Price, Consensus and EPS Surprise
Fresenius Medical Care AG Co KGaA price-consensus-eps-surprise-chart | Fresenius Medical Care AG Co KGaA Quote
Geographical Growth
North America
Revenues in the region grew 10% year over year and 7% at cc. On organic basis, sales in the region improved 3%.
EMEA
Revenues in this region increased 4% year over year and 4% cc in the quarter. On organic basis, sales in the region advanced 3%.
Asia-Pacific
Revenues in this region improved 4% year over year and 3% at cc in the reported quarter. On an organic basis, sales in the region improved 2%.
Latin America
Revenues in Latin America rose 4% year over year and 24% at cc. Organic growth in region was 17%.
Guidance
Following is the outlook provided in February, which excludes the impact of the COVID-19 pandemic.
For 2020, the company expects adjusted revenues and adjusted net income to improve at a mid-to-high-single digit rate.
Summing Up
Fresenius Medical reported mixed results in the first quarter. The company continues to gain from Health Care Products and Services units, which witnessed revenue growth in the quarter under review. Revenues in the North American, EMEA and Asia-Pacific regions also improved. In fact, management remains optimistic regarding the buyouts of Sound Physicians and NxStage Medical.
Furthermore, strong view for 2020 paints a brighter picture. Revenue growth in the reported quarter highlights the company’s underlying business development remaining intact and resiliency of its business model.
However, Fresenius Medical faces intense competition in the field of health care services, and sale of dialysis products, which remains a concern.
Zacks Rank
The company carries a Zacks Rank of 4 (Sell).
Key Picks
Some better-ranked stocks in the broader medical space are Aphria Inc. , Biogen Inc. (BIIB - Free Report) and Eli Lilly and Company (LLY - Free Report) .
Aphria reported third-quarter fiscal 2020 adjusted EPS of 2 cents, beating the Zacks Consensus Estimate of a loss of 4 cents. Net revenues of $64.4 million surpassed the consensus mark by 14.6%. The company carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Biogen currently carries a Zacks Rank #2. It reported first-quarter 2020 adjusted EPS of $9.14, surpassing the Zacks Consensus Estimate by 18.1%. Revenues of $3.53 billion outpaced the consensus mark by 3.2%.
Eli Lilly reported first-quarter 2020 EPS of $1.75, outpacing the Zacks Consensus Estimate by 12.9%. Revenues of $145.3 million surpassed the consensus estimate by 6.3%. The company currently sports a Zacks Rank #1.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>